{
  "source": "PA-Notification-Yoripath.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1464-1\nProgram Prior Authorization/Notification\nMedication Yorvipath® (palopegteriparatide)\nP&T Approval Date 12/2024\nEffective Date 3/1/2025\n1. Background:\nYorvipath® is a parathyroid hormone analog (PTH(1-34)) indicated for the treatment of\nhypoparathyroidism in adults.\nLimitations of Use:\n• Yorvipath was not studied for acute post-surgical hypoparathyroidism.\n• Titration scheme was only evaluated in adults who first achieved an albumin-corrected serum\ncalcium of at least 7.8 mg/dL using calcium and active vitamin D treatment.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Yorvipath will be approved based on all of the following criteria:\na. Diagnosis of hypoparathyroidism\n-AND-\nb. Yorvipath is not being used to treat acute post-surgical hypoparathyroidism\n-AND-\nc. Patient has achieved an albumin-corrected serum calcium of at least 7.8 mg/dL\nusing calcium and active vitamin D (e.g., calcitriol) treatment\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Yorvipath will be approved based on the following criterion:\na. Documentation of positive clinical response to Yorvipath therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\n© 2024 UnitedHealthcare Services, Inc.\n1\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Medical Necessity may be in place\n4. References:\n1. Yorvipath® [package insert]. Princeton, NJ: Ascendis Pharma, Inc.; August 2024.\nProgram Prior Authorization/Notification - Yorvipath (palopegter",
    ".\n• Medical Necessity may be in place\n4. References:\n1. Yorvipath® [package insert]. Princeton, NJ: Ascendis Pharma, Inc.; August 2024.\nProgram Prior Authorization/Notification - Yorvipath (palopegteriparatide)\nChange Control\n12/2024 New program.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}